Product Images Pregabalin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 14 images provide visual information about the product associated with Pregabalin NDC 71610-799 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 71610 0799 30

Aphena - Aphena

Chemical Structure - pregabalin 01

Figure 1 - pregabalin 02

This text provides information on the percentage of patients improved with different doses of Pregabalin and a placebo. The data displays the percentage improvement in pain from baseline for each treatment option.*

Figure 2 - pregabalin 03

Figure 3 - pregabalin 04

This text provides information on a clinical trial involving the use of Pregabalin at different dosages and a Placebo. The dosages evaluated were 300 mg two times a day, 150 mg two times a day, and 75 mg two times a day. The results show the percentage of patients improved and the percent improvement in pain from the baseline.*

Figure 4 - pregabalin 05

This text provides information about the percentage of patients who improved with different treatments for pain relief. The treatments mentioned include Pregabalin at doses of 100 mg and 200 mg three times a day, as well as a placebo. The percentage improvement in pain from baseline is also indicated at various points, such as 10%, 20%, 50%, 70%, 80%, and 90%.*

Figure 5 - pregabalin 06

This text provides information on the percent of patients improved with different dosages of Pregabalin and a placebo. It shows the percentage improvement in pain from the baseline with Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and the placebo.*

Figure 6 - pregabalin 07

This is not readable.*

Figure 7 - pregabalin 08

This document appears to be a table showing different studies (E1, E2, E3) and their corresponding tested doses in milligrams per day. The studies were conducted with varying dose levels, including Placebo, and only significant p-values are shown. The text also includes some numerical values and symbols related to the studies.*

Figure 9 - pregabalin 09

This is not a readable text.*

Figure 10 - pregabalin 10

Figure 11 - pregabalin 11

The text provides information about the percentage of subjects who showed improvement over a 12-week period when comparing Pregabalin to Placebo. This data is represented with numerical values ranging from 210 to 290, with a peak improvement of 100% reported.*

Figure 12 - pregabalin 12

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.